Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $3.67.

A number of brokerages have weighed in on LXRX. Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Piper Sandler cut their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. Leerink Partners reiterated a "market perform" rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Finally, Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Straight Path Wealth Management bought a new position in Lexicon Pharmaceuticals during the first quarter valued at approximately $29,000. Bayesian Capital Management LP bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $31,000. Wealth Enhancement Advisory Services LLC bought a new position in Lexicon Pharmaceuticals in the first quarter worth approximately $32,000. RPO LLC bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $33,000. Finally, Renaissance Technologies LLC bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $38,000. Institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Stock Down 0.0%

LXRX traded down $0.00 during midday trading on Wednesday, reaching $0.66. The company's stock had a trading volume of 3,186,387 shares, compared to its average volume of 6,614,882. The firm has a market capitalization of $238.55 million, a price-to-earnings ratio of -0.88 and a beta of 1.07. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $2.45. The stock's 50-day moving average is $0.56 and its 200-day moving average is $0.67.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The business had revenue of $1.26 million for the quarter, compared to analysts' expectations of $1.26 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. As a group, research analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.